

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tosato et al.

Application No.: To be assigned

Filed: Herewith

For: USE OF CALRETICULIN AND
CALRETICULIN FRAGMENTS TO INHIBIT
ENDOTHELIAL CELL GROWTH AND
ANGIOGENESIS, AND SUPPRESS TUMOR
GROWTH

Examiner: To be assigned

Date: April 5, 2001

Art Unit: To be assigned

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 5, 2001 as Express Mail Label No. EL754020413US in an envelope addressed to: BOX PCT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.



William D. Noonan, M.D.
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

BOX PCT
COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement before the mailing date of a first Office action on the merits. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP


By 

William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391 / Facsimile: (503) 228-9446



**INFORMATION DISCLOSURE
STATEMENT**



APPlicant

Docket: 4239-58378

App: To be assigned

Applicant: Tosato et al.

Filed: Herewith

Art Unit: To be assigned

U.S. PATENT DOCUMENTS

Init.*	Number	Date	Name	Class	Sub	Filed
	5,426,097	June 20, 1995	Stern et al.			
	5,591,716	Jan. 7, 1995	Siebert et al.			

FOREIGN PATENT DOCUMENTS

Number	Date	Country	Class	Sub	Filed
WO 95/13828	26 May 1995	PCT			
WO 96/23001	1 Aug. 1996	PCT			
WO 96/36643	21 Nov. 1996	PCT			
WO 00/50080	31 Aug. 2000	PCT			
2,140,814	24 July 1996	Canada			

OTHER DOCUMENTS


		Dai et al., <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 17(11):2359-2368, 1997 (abstract only); Medline abstract no. 1998073667, XP002133012
		Dedhar, <i>TIBS</i> , 19:269-271, 1994.
		Kishore et al., <i>Biochem. J.</i> , 322(2):543-550, 1997 (abstract only); Medline abstract no. 97218114, XP002133013
		Kuwabara et al., <i>J. Bio. Chem.</i> , 270(14):8179-8187, 1995.

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT



BY APPLICANT

Docket: 4239-58378

App: To be assigned

Applicant: Tosato et al.

Filed: Herewith

Art Unit: To be assigned

Kwon et al., *Mol. Biol. of the Cell*, 11:1433-1443, 2000.McDonnell et al., *J. Bio. Chem.*, 271(14):7891-7894, 1996.Michalak et al., *Biochem. J.*, 285:681-692, 1992.Nash et al., *Mol. & Cell. Biochem.*, 135:71-78, 1994.Pike et al., *Chemical Abstracts*, 130(14), abstract no. 177891, 1999; & *J. Experimental Medicine*, 188(12):2349-2356, 1998.Pike et al., *Blood*, 94(7):2461-2468, 1999.Rokeach et al., *Protein Engineering*, 4(8):981-987, 1997.Routsias et al., *Clinical and Experimental Immunology*, 91(3):437-441, 1993 (abstract only); Medline abstract no. 93185299, XP002133014.Sontheimer et al., *J. Invest. Med.*, 43(4):362-370, 1995.Stuart et al., *FEBS Letters*, 397:245-249, 1996.

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.